Advertisement
UK markets close in 5 hours 43 minutes
  • FTSE 100

    8,081.47
    +36.66 (+0.46%)
     
  • FTSE 250

    19,786.88
    -12.84 (-0.06%)
     
  • AIM

    754.58
    -0.29 (-0.04%)
     
  • GBP/EUR

    1.1629
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2431
    -0.0022 (-0.18%)
     
  • Bitcoin GBP

    53,398.75
    +156.31 (+0.29%)
     
  • CMC Crypto 200

    1,433.19
    +9.09 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.87
    -0.49 (-0.59%)
     
  • GOLD FUTURES

    2,327.00
    -15.10 (-0.64%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,196.34
    +58.69 (+0.32%)
     
  • CAC 40

    8,122.63
    +16.85 (+0.21%)
     

32,884 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE 8 JULY 2021 at 9.00 EEST

32,884 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 32,884 A shares have been converted into 32,884 B shares. The conversion has been entered into the Trade Register on 8 July 2021.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 35,006,523 A shares and 106,127,755 B shares. The number of votes of the company's shares is after the conversion 806,258,215.

Orion Corporation

Jari Karlson

CFO

Olli Huotari

SVP, Corporate Functions


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

ADVERTISEMENT

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.